![<?echo $_SERVER['SERVER_NAME'];?>](/template/twentyseventeen/skin/images/header.jpg)
According to China Drying News, "China's pharmaceutical industry will achieve a growth of 19-21% in 2012." On the 5th, Xu Ming, vice president of the China Medicare Association, told reporters. However, the export situation of enterprises is not optimistic. It is imperative to upgrade the industry and deepen the overseas market through “going globalâ€.
It is understood that the total size of the pharmaceutical industry this year will reach 1.8 trillion yuan, and the industry average profit level will be 10%. Among them, the pharmaceutical industry will achieve a sales scale of 900 billion yuan. In the fine-grained industry, the profit rate of biopharmaceuticals will be the highest, reaching 15%; the Chinese medicine will be 11%, the raw material drugs will be 9.8%, and the profitability of chemical drugs will be lower.
In terms of development trends, the export situation is still not optimistic. From January to October this year, China's pharmaceutical industry's export growth rate was 7.8%. Demand in the foreign market was declining. In the past, long-term single orders in Europe and America were shortened, and new customers were insufficiently sourced. As a result, the company’s costs increased rapidly and business risks increased.
In addition, Xu Ming pointed out that India’s threat to China’s pharmaceutical exports is increasing. From the second half of this year, China's pharmaceutical industry exports have entered a difficult period. Except for a small number of enterprises such as Hengrui Medicine, which have completed industrial upgrading and can achieve cross-cycle growth, most of the unprepared enterprises have encountered more difficulties than in 2009.
It is worth noting that in the face of the low tide of the development of the industry, more and more powerful companies have set their sights on overseas markets. According to Xu Ming, up to now, more than 40 Chinese pharmaceutical companies have invested in plants in the United States. In some parts of the United States, there are preferential conditions for foreign pharmaceutical companies in drug approval and market access. Therefore, such as Hengrui, Hisun, Huahai, including Tasly and other pharmaceutical companies, have all invested in the United States to build factories and open up markets. "If Mindray Medical, the company's products have even entered the United States local government procurement directory." Xu Ming told reporters.
Xu Ming believes that China's raw material medicine exports have ranked first in the world, but from the perspective of this year's situation, the previous exports of vitamin C, E are falling, the company's profit situation began to shrink, and some have already lost money. In the future, exports of specialty APIs, including pharmaceutical preparations, are in the ascendant. The Chinese pharmaceutical industry must complete structural adjustments and industrial upgrading in order to broaden its export path under increasingly stringent European and American regulatory regimes in the fiercely competitive overseas markets.
Take Huahai Pharmaceutical as an example. On June 25, 2007, Huahai Pharmaceuticals received an official letter from the US FDA confirming that Huahai's anti-AIDS drug Nevirapine formulation product and its production line passed the US FDA certification with zero defects. In fact, Huahai United States subsidiary was incorporated in New Jersey, which was named "American Drug Valley" as early as October 2004. "In many pharmaceutical companies, Huahai can take the lead in gaining US FDA certification, relying on management philosophy, equipment conditions, and quality awareness. The most important thing is talent." Huahai Pharmaceutical Chairman and General Manager Chen Baohua told reporters in this way.
Automatic Saw Blade Sharpening Machine,Sharpening Machine For Saw Blade,Sharpening Machine,Circular Saw Blade Sharpening Machine
GUANGDONG CHITTAK INTELLIGENT EQUIPMENT CO.,LTD , https://www.ctklasercutter.com